G

Glaukos Corp
D

GKOS

99.930
USD
-0.28
(-0.28%)
مغلق
حجم التداول
34,639
الربح لكل سهم
-1
العائد الربحي
-
P/E
-44
حجم السوق
5,710,052,763
أصول ذات صلة
ABT
ABT
-1.740
(-1.30%)
132.260 USD
ALGN
ALGN
-7.490
(-4.10%)
175.090 USD
BDX
BDX
-2.180
(-1.27%)
169.970 USD
EW
EW
-1.530
(-2.05%)
73.280 USD
E
EYE
0.015
(0.07%)
22.380 USD
G
GKOS
-0.279
(-0.28%)
99.930 USD
ISRG
ISRG
-7.05
(-1.36%)
511.91 USD
MDT
MDT
-1.740
(-1.98%)
86.210 USD
SYK
SYK
-3.85
(-1.02%)
373.31 USD
ZBH
ZBH
-1.960
(-2.13%)
90.220 USD
المزيد
الأخبار المقالات

العنوان: Glaukos Corp

القطاع: Healthcare
الصناعة: Medical Devices
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.